Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

This study is testing a combination of five drugs — tislelizumab (an immunotherapy), cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone — for people with a rare type of T-cell lymphoma called angioimmunoblastic T-cell lymphoma (AITL) that has come back or stopped responding to prior treatment. **You may be eligible if...** - You have been diagnosed with AITL (a specific type of T-cell lymphoma) confirmed by a tissue biopsy - Your lymphoma has returned or is no longer responding to prior treatment - You have at least one measurable tumor that can be tracked on scans - You are in good enough health to receive treatment - You are 18 years of age or older **You may NOT be eligible if...** - You have never been treated for AITL before (this study is for relapsed/refractory cases) - You have active autoimmune disease requiring treatment - You have serious heart, liver, or kidney problems - You have active infections (including HIV or hepatitis B/C) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.